URA, which is now valued at more than $5bn, is set to integrate Dexcom’s glucose capabilities with the Oura ring.

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.